Helus Pharma Inc.
Close on Oct 19, 2026
About Helus Pharma
Pharmaceutical Preparations, SIC 2834
Cybin Inc. is a Canadian pharmaceutical company that focuses on research and development activities within the pharmaceutical preparations sector. The organization operates through research operations and subsidiary entities, including Helus Pharma, Adelia, Journey, and Serenity. It maintains laboratory equipment, software, and intellectual property portfolios, such as patents and operating rights, to advance its scientific programs. Because the provided corporate records focus on development assets, research expenditures, and laboratory infrastructure rather than commercial sales, specific commercial customers and consumer segments are not detailed.
The enterprise conducts business and holds corporate subsidiaries across several countries, including Canada, the United States, Ireland, and the United Kingdom. Its international corporate structure includes Cybin IRL Limited and Cybin UK Ltd., alongside North American units. Cybin maintains its principal executive offices and corporate headquarters at 100 King Street West, Suite 5600, in Toronto, Ontario, Canada.
Summary of the business section of Helus Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Helus Pharma Inc.
- Founded
- 2019
- Headquarters
- Toronto, Ontario, Canada
- Address
- 100 King Street West, Suite 5600
- Phone
- (908) 764-8385
- Website
- www.helus.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- March 31
- Auditor
- Zeifmans LLP, Toronto, Ontario
Stock & identifiers
- Ticker
- HELP
- Exchange
- Nasdaq
- IPO date
- Sep 13, 2019
- Shares outstanding
- 52M, Mar 31, 2026
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-38 reverse, Jul 1, 2025; 1-for-38 reverse, Sep 19, 2024
- SEC CIK
- 1833141
- CUSIP
- 23256X407
- ISIN
- US23256X4079
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric H. L. So | Executive Chair, Director | 4,518,630 |
| Michael Halstead | Chief Executive Officer | 168,568 |
| Paul Glavine | Chief Growth Officer | 4,502,193 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 23, 2026 | Name change | Name changed from CYBIN INC. to Helus Pharma Inc. |
| Jan 2, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Jan 2, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |